JP5183808B2 - 置換トリアゾロ−ピリダジン誘導体 - Google Patents

置換トリアゾロ−ピリダジン誘導体 Download PDF

Info

Publication number
JP5183808B2
JP5183808B2 JP2011525250A JP2011525250A JP5183808B2 JP 5183808 B2 JP5183808 B2 JP 5183808B2 JP 2011525250 A JP2011525250 A JP 2011525250A JP 2011525250 A JP2011525250 A JP 2011525250A JP 5183808 B2 JP5183808 B2 JP 5183808B2
Authority
JP
Japan
Prior art keywords
compound
compounds
acid
deuterium
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011525250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501346A (ja
JP2012501346A5 (https=
Inventor
ハーブソン，スコット
Original Assignee
コンサート ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンサート ファーマシューティカルズ インコーポレイテッド filed Critical コンサート ファーマシューティカルズ インコーポレイテッド
Publication of JP2012501346A publication Critical patent/JP2012501346A/ja
Publication of JP2012501346A5 publication Critical patent/JP2012501346A5/ja
Application granted granted Critical
Publication of JP5183808B2 publication Critical patent/JP5183808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011525250A 2008-08-29 2009-08-28 置換トリアゾロ−ピリダジン誘導体 Expired - Fee Related JP5183808B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
US61/093,293 2008-08-29
PCT/US2009/055427 WO2010025407A1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013004449A Division JP5373982B2 (ja) 2008-08-29 2013-01-15 置換トリアゾロ−ピリダジン誘導体

Publications (3)

Publication Number Publication Date
JP2012501346A JP2012501346A (ja) 2012-01-19
JP2012501346A5 JP2012501346A5 (https=) 2012-10-18
JP5183808B2 true JP5183808B2 (ja) 2013-04-17

Family

ID=41721962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011525250A Expired - Fee Related JP5183808B2 (ja) 2008-08-29 2009-08-28 置換トリアゾロ−ピリダジン誘導体
JP2013004449A Expired - Fee Related JP5373982B2 (ja) 2008-08-29 2013-01-15 置換トリアゾロ−ピリダジン誘導体
JP2013194060A Pending JP2014058518A (ja) 2008-08-29 2013-09-19 置換トリアゾロ−ピリダジン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013004449A Expired - Fee Related JP5373982B2 (ja) 2008-08-29 2013-01-15 置換トリアゾロ−ピリダジン誘導体
JP2013194060A Pending JP2014058518A (ja) 2008-08-29 2013-09-19 置換トリアゾロ−ピリダジン誘導体

Country Status (17)

Country Link
US (4) US8003646B2 (https=)
EP (2) EP2328414B1 (https=)
JP (3) JP5183808B2 (https=)
KR (1) KR20110063479A (https=)
CN (2) CN104098578A (https=)
AU (1) AU2009285533B2 (https=)
BR (1) BRPI0912928A2 (https=)
CA (1) CA2735549A1 (https=)
DK (1) DK2328414T3 (https=)
EA (1) EA020071B1 (https=)
ES (1) ES2451542T3 (https=)
HR (1) HRP20140195T1 (https=)
MX (1) MX2011002278A (https=)
PL (1) PL2328414T3 (https=)
PT (1) PT2328414E (https=)
WO (1) WO2010025407A1 (https=)
ZA (1) ZA201102123B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014058518A (ja) * 2008-08-29 2014-04-03 Concert Pharmaceuticals Inc 置換トリアゾロ−ピリダジン誘導体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037194A1 (pt) 2008-10-03 2010-04-08 Instituto Alberto Luiz De Coimbra De Pós Graduação E Pesquisa De Engenharia - Coppe/Ufrj Dispositivo para remoção de fragmentos metálicos e elementos metálicos do interior de canáis radiculares de dentes e processo para remoção dos mesmos
JP2012531419A (ja) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
JP2014530870A (ja) * 2011-10-20 2014-11-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
HK1201270A1 (en) 2012-01-11 2015-08-28 Bayer Intellectual Property Gmbh Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2013170242A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
US20150158870A1 (en) * 2012-05-11 2015-06-11 Concert Pharmaceuticals Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia
EP4511025A4 (en) * 2022-04-20 2026-04-15 Engrail Therapeutics Inc GABAa receptor modulator salts, particles, and their uses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
KR20000029548A (ko) * 1996-07-25 2000-05-25 더블유. 지. 콜 가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체
HUP0100575A3 (en) * 1998-01-21 2003-03-28 Merck Sharp & Dohme Ltd Hoddes Triazolo-pyridazine derivatives as ligands for gaba receptors
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ATE284403T1 (de) * 1999-01-27 2004-12-15 Merck Sharp & Dohme Triazolopyridazinderivate als liganden für gaba- rezeptoren
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2004048980A1 (en) * 2002-11-28 2004-06-10 Neurosearch A/S Method for screening for compounds as potential sedatives or anxiolytics
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
AU2008232425A1 (en) * 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
CN104098578A (zh) * 2008-08-29 2014-10-15 康瑟特制药公司 取代的三唑并哒嗪衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014058518A (ja) * 2008-08-29 2014-04-03 Concert Pharmaceuticals Inc 置換トリアゾロ−ピリダジン誘導体

Also Published As

Publication number Publication date
BRPI0912928A2 (pt) 2015-08-04
DK2328414T3 (en) 2014-03-10
EA201100409A1 (ru) 2011-10-31
HRP20140195T1 (hr) 2014-04-11
US20100056529A1 (en) 2010-03-04
JP2012501346A (ja) 2012-01-19
ZA201102123B (en) 2011-12-28
CN102176826B (zh) 2014-08-20
US8921366B2 (en) 2014-12-30
JP2014058518A (ja) 2014-04-03
AU2009285533A2 (en) 2011-04-21
US20130225590A1 (en) 2013-08-29
EP2328414A4 (en) 2011-11-16
US8399467B2 (en) 2013-03-19
US20120004236A1 (en) 2012-01-05
KR20110063479A (ko) 2011-06-10
PL2328414T3 (pl) 2014-05-30
CA2735549A1 (en) 2010-03-04
JP5373982B2 (ja) 2013-12-18
US8003646B2 (en) 2011-08-23
PT2328414E (pt) 2014-03-17
ES2451542T3 (es) 2014-03-27
EP2716158A1 (en) 2014-04-09
WO2010025407A1 (en) 2010-03-04
EA020071B1 (ru) 2014-08-29
AU2009285533A1 (en) 2010-03-04
AU2009285533B2 (en) 2014-02-13
MX2011002278A (es) 2011-04-14
EP2328414B1 (en) 2013-12-11
EP2328414A1 (en) 2011-06-08
CN102176826A (zh) 2011-09-07
CN104098578A (zh) 2014-10-15
JP2013100322A (ja) 2013-05-23
US20150111895A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
JP5183808B2 (ja) 置換トリアゾロ−ピリダジン誘導体
US20090137457A1 (en) Pyrimidinedione derivatives
US8609673B2 (en) Vandetanib derivatives
JP2016512831A (ja) 重水素化されたパルボシクリブ
US20090192188A1 (en) Tetrahydroisoquinoline derivatives
US8071596B2 (en) Endothelin receptor antagonists
US8367674B2 (en) Piperazine derivatives
WO2018013625A1 (en) Deuterated miconazole
WO2009126844A2 (en) Derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof
US20110301113A1 (en) Pyridineamine derivatives
US20100120786A1 (en) Piperazine Derivatives
US20090197899A1 (en) 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
WO2009099620A1 (en) 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
AU2014202485A1 (en) Substituted triazolo-pyridazine derivatives
US20110104158A1 (en) Deuterium bearing analogs of anastrozole as aromatase inhibitors for the treatment of breast cancer
WO2010002451A1 (en) Naphthyridin derivatives
WO2009151613A1 (en) Oxybutynin derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120828

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120828

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130115

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees